Phenyl(2-(pyridin-3-ylmethylamino)thieno[3,2-d]pyrimidin-4-yl)methanone | 1197192-73-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Phenyl(2-(pyridin-3-ylmethylamino)thieno[3,2-d]pyrimidin-4-yl)methanone
• 英文别名: phenyl-[2-(pyridin-3-ylmethylamino)thieno[3,2-d]pyrimidin-4-yl]methanone
• CAS: 1197192-73-6
• 化学式: C₁₉H₁₄N₄OS
• 分子量: 346.412
• InChiKey: NJLNJHCKQVRQDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  96
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-氨甲基吡啶 、 2-chlorothieno[3,2-d]pyrimidin-4-yl phenylmethanone 以 乙醇 为溶剂， 反应 18.0h， 生成 Phenyl(2-(pyridin-3-ylmethylamino)thieno[3,2-d]pyrimidin-4-yl)methanone
  参考文献：
  名称：

  Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor

  摘要：

  We herein report the discovery of a novel class of antagonists of the human adenosine A2B receptor. This low molecular weight scaffold has been optimized to offer derivatives with potential utility for the alleviation of conditions associated with this receptor subtype, such as nociception, diabetes, asthma and COPD. Furthermore, preliminary pharmacokinetic analysis has revealed compounds with profiles suitable for either inhaled or systemic routes of administration. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.08.040

文献信息

• Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor
  作者：Simon T. Bedford、Karen R. Benwell、Teresa Brooks、Ijen Chen、Mike Comer、Sarah Dugdale、Tim Haymes、Allan M. Jordan、Guy A. Kennett、Anthony R. Knight、Burkhard Klenke、Loic LeStrat、Angela Merrett、Anil Misra、Sean Lightowler、Anthony Padfield、Karine Poullennec、Mark Reece、Heather Simmonite、Melanie Wong、Ian A. Yule

  DOI：10.1016/j.bmcl.2009.08.040

  日期：2009.10

  We herein report the discovery of a novel class of antagonists of the human adenosine A2B receptor. This low molecular weight scaffold has been optimized to offer derivatives with potential utility for the alleviation of conditions associated with this receptor subtype, such as nociception, diabetes, asthma and COPD. Furthermore, preliminary pharmacokinetic analysis has revealed compounds with profiles suitable for either inhaled or systemic routes of administration. (C) 2009 Elsevier Ltd. All rights reserved.